Interventional Cardiology Resource Center Editorial Programs

 
 
  • ISCHEMIA: Do Baseline Data Hint at Triumph for OMT?   The success of OMT and the decline of patients with severe ischemia may make it difficult for ISCHEMIA to show benefit for revascularization, predicts Mayo Clinic's Raymond Gibbons, MD.
  • Women as One: 'The Sky's the Limit' for Women in Medicine   Roxana Mehran, MD, co-founder of Women as One, explains its mission to coach and mentor female physicians to develop leadership skills, learn negotiation tactics, and maximize their talents.
  • MitraClip for Secondary MR: Patient Selection Will Be Key   Wayne Batchelor, MD, and Catherine Otto, MD, discuss MitraClip for secondary MR. With FDA approval for this indication, how should cardiologists select patients to ensure COAPT-like results ?
  • Hopeful Heart: Hope for Improving QoL in Depressed HF Patients   'Depression kills,' says Bruce Rollman, MD, the lead author of the Hopeful Heart study. Screening can identify HF patients at risk for depression and improve outcomes.
  • ACC 2019What Will a 'Historic Day' for TAVR Mean in Clinical Practice?   Raj Makkar, MD, discusses the PARTNER-3 and Evolut trials of transcatheter aortic valve replacement in low-surgical-risk patients and his registry data on TAVR for bicuspid aortic stenosis at ACC.19.
  • ACC 2019Quick Thoughts on the Wrap-IT Trial An antibiotic-impregnated envelope casing for cardiac implantable devices may lower the risk for infection, but is it enough to justify the costs?
  • Cirrhosis and Surgery: How Do We Prevent Unnecessary Risk?   Dr David Johnson on a new review's valuable advice for identifying preoperative red flags in patients with cirrhosis.
  • Interventional Cardiology: Physician and Proceduralist 'I do not want to be known as a high- or a low-volume operator,' writes, Jaya Mallidi, MD, in a plea for her field to value critical thinking as much as it celebrates the latest Impella case.
  • Life and Times of Leading Cardiologists: Holger Thiele   Holger Thiele's career in cardiogenic shock began in West Berlin where he witnessed the fall of the wall and moved to Leipzig to pursue cardiology. This former ironman still bikes to the hospital.
  • Dual vs Triple Antithrombotic Therapy? The Debate Continues   Is a NOAC plus an antiplatelet drug enough to prevent thromboses? Stroke? What doses and combinations are safest? Christian Ruff, Mike Gibson, and Chris Cannon examine the evidence.
  • Mandrola's Top 10 Cardiology Stories of 2018 From blood pressure management in the community to a study on potentially biased referees -- John Mandrola reviews his picks for the year's big stories in cardiology and medicine.
  • AHA 2018Think You're Immune From Bias? Think Again John Mandrola, MD, is intrigued by two studies at AHA that track the cognitive and financial biases that may influence what physicians do in practice and how they write and read research papers.
  • CV Risk: Can Prescription Omega-3 REDUCE-IT?   Low-dose omega-3 flopped for CV risk reduction. Melissa Walton-Shirley, MD, dissects the REDUCE-IT trial from AHA, which used high-dose prescription EPA, with principal investigator, Deepak Bhatt, MD.
  • Mandrola Previews AHA 2018 Among the highlights for the upcoming American Heart Association Scientific Sessions are studies on omega-3, inflammation, a potential EP breakthrough, and yoga. Not to mention new lipid guidelines.
  • Vulnerable Plaque: Are Targeted Therapies Within Reach? Recent studies aim to move vulnerable plaque identification into the cath lab routine. Can these tests pinpoint who will benefit most from aggressive pharmacologic therapies and maybe even stents?
  • Requiem for Aspirin in Dual Antiplatelet Therapy?   Mounting evidence makes Dr Michelle O'Donoghue wonder whether the perennial question on the optimal duration of DAPT should be revised to: How soon can you drop the aspirin? Have you changed your practice?
  • Closing the Office Door for the Last Time With a heavy heart, Melissa Walton-Shirley bids farewell to full-time practice. Ailing parents and RVU demands drive this transition to a new stage in her career.
  • TCT 2018MitraClip for Secondary MR -- The Redux Two conflicting studies on the percutaneous treatment of secondary mitral regurgitation in patients with heart failure lead John Mandrola, MD, to compare and contrast as we await the tiebreaker third.
  • Beta-Blockade After MI: No Practice Should Be Set in Stone Meta-analyses suggest little benefit for beta-blockers in contemporary patients with normal ejection fraction after MI. What other dogma should be revisited in light of an evolving evidence base?
  • Who Is the 'Cardiometabolic Specialist'?   With new diabetes drugs available that lower cardiovascular risk, the question arises over which specialty will manage this area of medicine. Or will a new specialty emerge?
viagra 100mg

viagra-on.com

steroid-pharm.com/